Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DCFPyL PET/MRI vs mpMRI for Prostate Cancer Diagnosis
NCT04910425Phase 2Withdrawn
- Sponsor
- Northwestern University
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of piflufolastat f 18 in prostate cancer (PCa), sponsored by Northwestern University. Primary endpoint: 18-F-DCFPyL PET vs mpMRI for the diagnosis of clinically significant prostate cancer up to 30 days. Planned start Jun 2023; status: withdrawn.
02
Drugs
piflufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04910425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910425.